PriceTargets.com logo

Amylyx Pharmaceuticals - AMLX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.43
  • Forecasted Upside: 118.52%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$5.23 As of 11/20/2024 01:00 AM ET
▲ +0.01 (0.19%)

This chart shows the closing price for AMLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amylyx Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMLX

Analyst Price Target is $11.43
▲ +118.52% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Amylyx Pharmaceuticals in the last 3 months. The average price target is $11.43, with a high forecast of $36.00 and a low forecast of $3.00. The average price target represents a 118.52% upside from the last price of $5.23.

This chart shows the closing price for AMLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 contributing investment analysts is to moderate buy stock in Amylyx Pharmaceuticals. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/18/2024Baird R WUpgradeHold ➝ Strong-Buy
11/18/2024Robert W. BairdUpgradeNeutral ➝ Outperform$3.00 ➝ $11.00
11/8/2024HC WainwrightBoost TargetBuy ➝ Buy$8.00 ➝ $12.00
10/23/2024Bank of AmericaUpgradeNeutral ➝ Buy$4.20 ➝ $10.00
10/18/2024Leerink PartnersSet TargetMarket Perform ➝ Market Perform$4.00
10/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
7/12/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$3.00 ➝ $4.00
7/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
6/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
5/14/2024MizuhoLower TargetNeutral ➝ Neutral$4.00 ➝ $3.00
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00
4/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00
3/18/2024MizuhoDowngradeBuy ➝ Neutral
3/11/2024Leerink PartnrsDowngradeOutperform ➝ Market Perform
3/11/2024Leerink PartnersDowngradeOutperform ➝ Market Perform
3/11/2024Robert W. BairdDowngradeOutperform ➝ Neutral
3/8/2024The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral
3/8/2024Evercore ISIReiterated RatingOutperform ➝ In-Line
1/3/2024Robert W. BairdInitiated CoverageOutperform$37.00
12/21/2023MizuhoLower TargetBuy ➝ Buy$46.00 ➝ $27.00
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$36.00
11/10/2023HC WainwrightLower TargetBuy ➝ Buy$50.00 ➝ $42.00
11/10/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$46.00 ➝ $40.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$50.00
7/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$50.00
7/24/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$45.00 ➝ $49.00
6/26/2023CitigroupLower Target$53.00 ➝ $48.00
5/15/2023MizuhoLower Target$52.00 ➝ $50.00
3/30/2023MizuhoInitiated CoverageBuy$52.00
3/14/2023The Goldman Sachs GroupBoost TargetNeutral$41.00 ➝ $47.00
3/14/2023HC WainwrightReiterated RatingBuy$50.00
3/14/2023CitigroupBoost TargetBuy$51.00 ➝ $54.00
2/15/2023HC WainwrightReiterated RatingBuy$50.00
1/5/2023Bank of AmericaInitiated CoverageBuy$50.00
11/16/2022CitigroupBoost Target$51.00
10/24/2022HC WainwrightBoost TargetBuy$35.00 ➝ $50.00
10/3/2022CitigroupBoost TargetBuy$48.00 ➝ $50.00
9/9/2022The Goldman Sachs GroupBoost TargetNeutral$22.00 ➝ $40.00
9/8/2022Leerink PartnersBoost TargetOutperform$31.00 ➝ $50.00
9/8/2022CitigroupBoost TargetBuy$35.00 ➝ $48.00
7/6/2022CitigroupBoost TargetBuy$33.00 ➝ $37.00
6/14/2022CitigroupBoost TargetBuy$32.00 ➝ $33.00
6/6/2022CitigroupUpgradeBuy$32.00
5/25/2022CitigroupInitiated CoverageBuy$21.00
2/2/2022Evercore ISIInitiated CoverageOutperform
2/1/2022Leerink PartnersReiterated RatingOutperform$50.00
2/1/2022The Goldman Sachs GroupInitiated CoverageBuy$36.00
2/1/2022HC WainwrightReiterated RatingBuy$35.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 34 positive mentions
  • 6 negative mentions
  • 5 very negative mentions
Mentions as of
4/25/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 5 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 5 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Amylyx Pharmaceuticals logo
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $5.23
Low: $5.09
High: $5.39

50 Day Range

MA: $4.28
Low: $2.49
High: $7.03

52 Week Range

Now: $5.23
Low: $1.58
High: $19.95

Volume

934,367 shs

Average Volume

2,022,290 shs

Market Capitalization

$358.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Amylyx Pharmaceuticals?

The following sell-side analysts have issued reports on Amylyx Pharmaceuticals in the last twelve months: Baird R W, Bank of America Co., Deutsche Bank Aktiengesellschaft, Evercore ISI, HC Wainwright, Leerink Partners, Leerink Partnrs, Mizuho, Robert W. Baird, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for AMLX.

What is the current price target for Amylyx Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Amylyx Pharmaceuticals in the last year. Their average twelve-month price target is $11.43, suggesting a possible upside of 118.5%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting AMLX will reach $36.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $3.00 for Amylyx Pharmaceuticals in the next year.
View the latest price targets for AMLX.

What is the current consensus analyst rating for Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals currently has 5 hold ratings, 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AMLX.

What other companies compete with Amylyx Pharmaceuticals?

Other companies that are similar to Amylyx Pharmaceuticals include Spyre Therapeutics, Travere Therapeutics, Ocular Therapeutix, Day One Biopharmaceuticals and Praxis Precision Medicines. Learn More about companies similar to Amylyx Pharmaceuticals.

How do I contact Amylyx Pharmaceuticals' investor relations team?

The company's listed phone number is 617-682-0917 and its investor relations email address is [email protected]. The official website for Amylyx Pharmaceuticals is amylyx.com. Learn More about contacing Amylyx Pharmaceuticals investor relations.